Luigi Sacco Hospital

Running trials

• Recruiting

  High Resolution Imaging OCT Study

  NCT07338461· Heidelberg Engineering GmbH· Source

• Enrolling by invitation

  Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

  NCT07256392· Phase 3· Celldex Therapeutics· Source

• Active, not recruiting

  A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar

  NCT07160816· Novo Nordisk A/S· Source

• Recruiting

  Prevention ICONA Dedicated Ensemble

  NCT07186244· Fondazione ICONA· Source

• Recruiting

  Multicenter Italian Cohort Study on Tuberculosis in Pediatric Age

  NCT06289660· Meyer Children's Hospital IRCCS· Source

• Recruiting

  Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

  NCT03994471· Phase 3· Iperboreal Pharma Srl· Source

• Active, not recruiting

  An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

  NCT05300724· Genentech, Inc.· Source

• Active, not recruiting

  Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

  NCT03595592· Phase 3· Fondazione Michelangelo· Source

• Active, not recruiting

  Development of Novel Clinical Endpoints in Intermediate AMD

  NCT03349801· Frank G. Holz· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease1 recruiting
• Chronic spontaneous urticaria1 recruiting
• Diabetic eye disease1 recruiting
• HIV1 recruiting
• Macular degeneration1 recruiting
• Tuberculosis1 recruiting

Closed trials

• Completed

  RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular Diseases (ALIGNED)

  NCT06935578· Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta· Source

• Terminated

  A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

  NCT06025110· Phase 2· ITB-Med LLC· Source

• Completed

  Registry of Asthma Patients Initiating DUPIXENT®

  NCT04287621· Regeneron Pharmaceuticals· Source

• Completed

  Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

  NCT02620280· Phase 3· Fondazione Michelangelo· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Macular degeneration16 works · 3 trials